Publications (55) Publications in which a researcher has participated View referenced research data.

filter_list Pharmacology (medical)

2023

  1. Recommendations of the Spanish Antibiogram Committee (COESANT) for in vitro susceptibility testing of antimicrobial agents by disk diffusion

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 41, Núm. 9, pp. 571-576

2022

  1. Impact of Peptidoglycan Recycling Blockade and Expression of Horizontally Acquired β-Lactamases on Pseudomonas aeruginosa Virulence

    Microbiology Spectrum, Vol. 10, Núm. 1

  2. Rapid Identification and Classification of Pathogens That Produce Carbapenemases and Cephalosporinases with a Colorimetric Paper-Based Multisensor

    Analytical Chemistry, Vol. 94, Núm. 26, pp. 9442-9449

2020

  1. Clinically relevant epithelial lining fluid concentrations of meropenem with ciprofloxacin provide synergistic killing and resistance suppression of hypermutable pseudomonas aeruginosa in a dynamic biofilm model

    Antimicrobial Agents and Chemotherapy, Vol. 64, Núm. 7

  2. Predicting antimicrobial resistance in Pseudomonas aeruginosa with machine learning-enabled molecular diagnostics

    EMBO Molecular Medicine, Vol. 12, Núm. 3

  3. Recommendations of the Spanish Antibiogram Committee (COESANT) for selecting antimicrobial agents and concentrations for in vitro susceptibility studies using automated systems

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 4, pp. 182-187

2019

  1. Challenging antimicrobial susceptibility and evolution of resistance (oxa-681) during treatment of a long-term nosocomial infection caused by a pseudomonas aeruginosa ST175 Clone

    Antimicrobial Agents and Chemotherapy, Vol. 63, Núm. 10

  2. Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis

    Clinical Pharmacokinetics, Vol. 58, Núm. 2, pp. 143-156

  3. Higher MICs (>2 mg/L) Predict 30-Day Mortality in Patients with Lower Respiratory Tract Infections Caused by Multidrug- And Extensively Drug-Resistant Pseudomonas aeruginosa Treated with Ceftolozane/Tazobactam

    Open Forum Infectious Diseases, Vol. 6, Núm. 10

  4. In vitro and in vivo activities of -lactams in combination with the novel -lactam enhancers zidebactam and WCK 5153 against multidrug-resistant metallo-lactamase-producing klebsiella pneumoniae

    Antimicrobial Agents and Chemotherapy, Vol. 63, Núm. 5

  5. Regulation of AmpC-Driven β-Lactam Resistance in Pseudomonas aeruginosa: Different pathways, different signaling

    mSystems, Vol. 4, Núm. 6

  6. Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology

    Journal of Antimicrobial Chemotherapy, Vol. 74, Núm. 7, pp. 1825-1835

  7. Therapeutic Efficacy of LN-1-255 in Combination with Imipenem in Severe Infection Caused by Carbapenem-Resistant Acinetobacter baumannii

    Antimicrobial Agents and Chemotherapy, Vol. 63, Núm. 10

2018

  1. Antibiotic selection in the treatment of acute invasive infections by pseudomonas aeruginosa: Guidelines by the Spanish society of chemotherapy

    Revista Espanola de Quimioterapia, Vol. 31, Núm. 1, pp. 78-100

  2. Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 37, Núm. 11, pp. 2191-2200

  3. Deciphering β-lactamase-independent β-lactam resistance evolution trajectories in Pseudomonas aeruginosa

    Journal of Antimicrobial Chemotherapy, Vol. 73, Núm. 12, pp. 3322-3331

  4. Identifying and exploiting genes that potentiate the evolution of antibiotic resistance

    Nature Ecology and Evolution, Vol. 2, Núm. 6, pp. 1033-1039

  5. Increased Antimicrobial Resistance in a Novel CMY-54 AmpC-Type Enzyme with a GluLeu217-218 Insertion in the Ω-Loop

    Microbial Drug Resistance, Vol. 24, Núm. 5, pp. 527-533

  6. Optimization of a meropenem-tobramycin combination dosage regimen against hypermutable and nonhypermutable pseudomonas aeruginosa via mechanism-based modeling and the hollow-fiber infection model

    Antimicrobial Agents and Chemotherapy, Vol. 62, Núm. 4

  7. Phenylboronic Acid Derivatives as Validated Leads Active in Clinical Strains Overexpressing KPC-2: A Step against Bacterial Resistance

    ChemMedChem, Vol. 13, Núm. 7, pp. 713-724